Camurus AB CAMRF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $50.71
- Day Range
- $46.15–46.15
- 52-Week Range
- $21.81–51.65
- Bid/Ask
- $14.47 / $51.65
- Market Cap
- $2.66 Bil
- Volume/Avg
- 226 / 3,095
Key Statistics
- Price/Earnings (Normalized)
- 56.52
- Price/Sales
- 16.43
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company's product pipeline includes CAM2029, CAM4072 and CAM2043.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 215
- Website
- https://www.camurus.com
Comparables
Valuation
|
Metric
|
CAMRF
|
BIOA B
|
CALTX
|
|---|---|---|---|
Price/Earnings (Normalized) | 56.52 | 75.88 | — |
Price/Book Value | 17.18 | 16.46 | 17.63 |
Price/Sales | 16.43 | 28.01 | 4.89 |
Price/Cash Flow | 43.30 | 58.19 | — |
Price/Earnings
CAMRF
BIOA B
CALTX
Financial Strength
|
Metric
|
CAMRF
|
BIOA B
|
CALTX
|
|---|---|---|---|
Quick Ratio | 4.08 | 9.15 | 2.85 |
Current Ratio | 4.41 | 9.22 | 3.13 |
Interest Coverage | 412.44 | 739.59 | −5.64 |
Quick Ratio
CAMRF
BIOA B
CALTX
Profitability
|
Metric
|
CAMRF
|
BIOA B
|
CALTX
|
|---|---|---|---|
Return on Assets (Normalized) | 31.10% | 22.04% | −24.68% |
Return on Equity (Normalized) | 39.62% | 24.17% | −89.92% |
Return on Invested Capital (Normalized) | 37.45% | 21.25% | −31.14% |
Return on Assets
CAMRF
BIOA B
CALTX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fzlhhglw | Dykr | $572.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Znlcpqfcz | Vvmjjt | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Lsrrnqjb | Hjtxvb | $99.6 Bil | |
MRNA
| Moderna Inc | Lgzgzxwrl | Mlsz | $42.7 Bil | |
ARGX
| argenx SE ADR | Dygmznfbm | Wjxz | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Csfgxlfvl | Ybv | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tplznvys | Xdxtxd | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lfyqgdrx | Bvhwlcf | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hsbrvpvwk | Fpzwln | $12.7 Bil | |
INCY
| Incyte Corp | Zrbgscqb | Nhbkbh | $11.9 Bil |